SPY343.38+1.37 0.40%
DIA282.95+0.92 0.33%
IXIC11,516.49+37.51 0.33%

Syros to Present Initial Data from Phase 1 Clinical Trial of SY-5609 at EORTC-NCI-AACR Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present initial data from the ongoing

· 10/09/2020 07:33

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present initial data from the ongoing dose escalation portion of its Phase 1 clinical trial of SY-5609, its highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor, in patients with select solid tumors. The data will be presented in a poster session at the 32nd EORTC-NCI-AACR Symposium, taking place virtually October 24-25, 2020, and will include data on safety, pharmacokinetics and pharmacodynamics.

The abstract is now available on the EORTC-NCI-AACR conference website at https://event.eortc.org/ena2020/. The presentation will be available for on-demand viewing on the ENA website starting Saturday, Oct. 24, 2020.

Details of the poster presentation are as follows:

Presentation Title: Early evidence of dose-dependent pharmacodynamic activity following treatment with SY-5609, a highly selective and potent oral CDK7 inhibitor, in patients with advanced solid tumors
Session Title: New Drugs
Presenter: Kyriakos P. Papadopoulos, M.D., South Texas Accelerated Research Therapeutics
Abstract Number: 180